TrialScience advances2025

Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine.

Constantino López-Macías et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.